Dublin, Sept. 16, 2021 (GLOBE NEWSWIRE) -- The "Companion Diagnostics: Technologies and Global Market 2021-2026" report has been added to ResearchAndMarkets.com's offering.
The global market for companion diagnostics (CDx) is estimated to grow from $5.4 billion in 2021 to reach $10.7 billion by 2026, at a compound annual growth rate (CAGR) of 14.6% during the forecast period of 2021-2026.
The global market for NGS-CDx (next-generation sequencing) is estimated to grow from $1.3 billion in 2021 to reach $3.3 billion by 2026, at a CAGR of 20.9% during the forecast period of 2021-2026.
The global market for PCR-CDx (polymerase chain reaction) is estimated to grow from $762.0 million in 2021 to reach $1.6 billion by 2026, at a CAGR of 15.3% during the forecast period of 2021-2026.
This report provides a comprehensive analysis of the CDx market in the global context, including market forecasts and sales through 2026. The report analyzes the market by segmenting it into the various product offerings: consumables (reagents, kits and panels), services and software. The segmentation also provides analysis by popular technology types such as PCR, next-generation sequencing, in situ hybridization (ISH), immunohistochemistry (IHC) and others.
This study surveys the CDx market by application into different therapeutic areas. The market is also assessed in three major geographic regions: North America, Europe and Asia-Pacific (APAC). The APAC markets include countries like India, China, Korea, Japan, Taiwan, Australia and New Zealand.
The report features new product developments, clinical trials and patents boosting the growth of this market in the global context.
This report provides comprehensive profiles of market players in the industry. The industry structure chapter focuses on the changing market trends, market players and their leading products. This chapter also covers the mergers and acquisitions and any other collaborations or partnerships that happened during the evaluation period of this report that are expected to shape the industry.
Factors such as strengths, weaknesses, threats and opportunities that are expected to play a role in this market are evaluated in detail.
The scope of the report excludes the in vitro diagnostic products and their regulatory aspects. Also excluded are the nucleic acid-based tests in general, focusing solely on the companion diagnostics that meet the FDA definition.
The Report Includes
53 data tables and 44 additional tables
An overview of the global market for companion diagnostic (CDx) technologies
Analyses of the global market trends, with data from 2019-2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
Evaluation of current market size, market forecast, and technological advancements within the industry and discussion on technical issues related to biomarker stability and storage
Market share analysis of global CDx market by solution and type of test, technology, application, and geographic region
Information on biomarkers, their role in precision medicine and discussion on the potential use of biomarkers in the development of companion diagnostics (CDx)
Insights into CDx approvals and FDA guidelines for new drugs and description of predictive genomic biomarkers for immunotherapy including microsatellite instability (MSI) and tumor mutational burden (TMB)
Coverage of new CDx product developments, clinical trials, patents issued, mergers and acquisitions, partnerships, collaborations and other effective market development strategies
Comprehensive company profiles of major industry players, including Adaptive Biotechnologies, Exact Sciences Corp., Exosome Diagnostics Inc., Foundation Medicine Inc., Myriad Genetic Laboratories Inc., Roche Molecular Systems Inc., Prometheus Biosciences, Qiagen and Thermo Fisher Scientific Inc.
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Personalized Medicine and Biomarkers
Companion Diagnostics and Complementary Diagnostics
Companion Diagnostic Development
Technologies Used in CDx
Applications of CDx
Regulatory Aspects of CDx
Chapter 4 Market Breakdown by Solution and Type of Test
Global Market for Companion Diagnostic by Type of Test
Global Market for Companion Diagnostics by Solution
Global Market for Companion Diagnostic Solutions by Region
Chapter 5 Market Breakdown by Technology
Global Market for Companion Diagnostics by Technology
Global Market for Companion Diagnostic Technologies by Region
In Situ Hybridization
Polymerase Chain Reaction
CDx Development Services
Chapter 6 Market Breakdown by Application
Global Market for Companion Diagnostic Applications
Global Market for Companion Diagnostic Applications by Region
LDT-CDx by Application
CDx in Non-oncology Areas
Chapter 7 Industry Structure
Stakeholders in Companion Diagnostics
Driving Trends in Companion Diagnostics
Business Models of Companion Diagnostics
Grants and Funding in Companion Diagnostics
Collaborations and Partnerships
Mergers and Acquisitions
Leading Market Players in Companion Diagnostics Market
Leading Market Players in IHC Market
Leading Market Players in ISH Market
Leading Market Players in PCR Market
Leading Market Players in NGS Market
Leading Market Players in Genotyping Market
Leading Market Players in Other CDx Technologies Market
Chapter 8 Patent Review
Patents in Companion Diagnostics Market
Patents by Year
Patents by Application
Patents by Company
Patents by Country
Patents by Assignee
Chapter 9 Clinical Trials Analysis
Clinical Trials and CDx
Clinical Trials Analysis
Clinical Trials Analysis by Type of Study
Clinical Trials Analysis by Status
Clinical Trials Analysis by Phase
Clinical Trials Analysis by Technology
Clinical Trial Analysis by Application
Clinical Trial Analysis by Therapeutic Area
Companies with Companion Diagnostics in Clinical Trials
Chapter 10 Analysis of Market Opportunities
Chapter 11 Company Profiles
Abbott Laboratories Inc.
Adaptive Biotechnologies Corp.
Advanced Cell Diagnostics Inc.
Agilent Technologies Inc.
Amoy Diagnostics Co., Ltd.
Almac Group Ltd.
Autogenomics Inc. (Acquired By Prescient Medicine)
Clinical Micro Sensors Inc. (Now Genmark Diagnostics Inc.)
Exact Sciences Corp.
F. Hoffmann-La Roche Ltd.
Foundation Medicine Inc.
Guardant Health Inc.
Leica Biosystems (Division Of Leica Microsystems Inc.)
Luminex Molecular Diagnostics Inc. (Luminex Corp.)
Monogram Biosciences Inc. (Part Of Labcorp)
Myriad Genetics Inc.
Quest Diagnostics Inc.
Resolution Bioscience Inc.
Resonance Health Ltd.
Siemens Healthineers Ag
Spartan Bioscience Inc.
Thermo Fisher Scientific Inc.
Vela Diagnostics Inc.
Chapter 12 Appendix: Acronyms
For more information about this report visit https://www.researchandmarkets.com/r/9ceuh8
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900